A new trading day began on Friday, with Akebia Therapeutics Inc. (NASDAQ: AKBA) stock price up 0.75% from the previous day of trading, before settling in for the closing price of $1.33. AKBA’s price has ranged from $0.78 to $2.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 5.16% over the past five years. Meanwhile, its annual earnings per share averaged 13.10%. With a float of $199.72 million, this company’s outstanding shares have now reached $210.29 million.
Let’s look at the performance matrix of the company that is accounted for 167 employees. In terms of profitability, gross margin is 61.9%, operating margin of -20.21%, and the pretax margin is -23.18%.
Akebia Therapeutics Inc. (AKBA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Akebia Therapeutics Inc. is 5.03%, while institutional ownership is 24.20%. The most recent insider transaction that took place on May 13 ’24, was worth 15,140. In this transaction SVP, Chief Legal Officer of this company sold 12,016 shares at a rate of $1.26, taking the stock ownership to the 651,243 shares. Before that another transaction happened on May 13 ’24, when Company’s SVP, Chief Operating Officer sold 34,840 for $1.26, making the entire transaction worth $43,898. This insider now owns 672,092 shares in total.
Akebia Therapeutics Inc. (AKBA) Performance Highlights and Predictions
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.08 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.10% per share during the next fiscal year.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Trading Performance Indicators
Here are Akebia Therapeutics Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.20, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.26 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics Inc. (NASDAQ: AKBA) saw its 5-day average volume 0.93 million, a negative change from its year-to-date volume of 3.15 million. As of the previous 9 days, the stock’s Stochastic %D was 67.82%. Additionally, its Average True Range was 0.05.
During the past 100 days, Akebia Therapeutics Inc.’s (AKBA) raw stochastic average was set at 69.23%, which indicates a significant increase from 62.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.76% in the past 14 days, which was lower than the 66.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3803, while its 200-day Moving Average is $1.3830. Nevertheless, the first resistance level for the watch stands at $1.3533 in the near term. At $1.3667, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3933. If the price goes on to break the first support level at $1.3133, it is likely to go to the next support level at $1.2867. Assuming the price breaks the second support level, the third support level stands at $1.2733.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Key Stats
With a market capitalization of 281.79 million, the company has a total of 209,596K Shares Outstanding. Currently, annual sales are 194,620 K while annual income is -51,930 K. The company’s previous quarter sales were 43,650 K while its latest quarter income was -8,580 K.
